Movsas B, Teruya-Feldstein J, Smith J, Glatstein E, Epstein A H
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.
Chest. 1998 Aug;114(2):648-52. doi: 10.1378/chest.114.2.648.
Primary cardiac sarcomas carry a dismal prognosis with no known curative therapy using standard treatment approaches. By its very location, the possibility of a radical complete resection--the underlying principle in the management of any soft-tissue sarcoma--is precluded. While literally in a continuous "blood bath," cardiac sarcomas are associated with a very high rate of hematogenous metastases. This report describes the management of a case in a 51-year-old white man with a high-grade unresectable cardiac sarcoma who was treated with hyperfractionated (twice daily) radiotherapy to a total dose of 7,050 cGy along with a radiosensitizer, (5'-iododeoxyuridine. The patient currently is disease-free and functioning well more than 5 years following this novel treatment approach.
原发性心脏肉瘤预后不佳，采用标准治疗方法尚无已知的治愈性疗法。因其所在位置，根治性完全切除（这是任何软组织肉瘤治疗的基本原则）的可能性不存在。心脏肉瘤虽处于持续的“血池”中，却伴有极高的血行转移率。本报告描述了一名51岁白人男性患者的治疗情况，该患者患有高级别无法切除的心脏肉瘤，接受了超分割（每日两次）放疗，总剂量达7050厘戈瑞，并使用了放射增敏剂（5'-碘脱氧尿苷）。采用这种新的治疗方法后，该患者目前已无疾病且状况良好，已超过5年。
